Ultragenyx Pharmaceutical (RARE) Receivables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Receivables for 14 consecutive years, with $122.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 20.51% year-over-year to $122.0 million; the TTM figure through Mar 2026 stood at $122.0 million (up 20.51% YoY), while the FY2025 annual figure was $159.0 million, up 28.23% from the prior year.
• Receivables climbed to $122.0 million in Q1 2026 per RARE's latest filing, from $2.0 million in the prior quarter.
• Across five years, Receivables topped out at $125.4 million in Q2 2025 and bottomed at $2.0 million in Q4 2025.
• Historically, Receivables has averaged $77.4 million across 5 years, with a median of $79.7 million in 2023.
• Annual changes were most pronounced in 2023 — Receivables surged 131.82% — and 2025, when it sank 98.39%.
• Ultragenyx Pharmaceutical's Receivables stood at $33.9 million in 2022, then surged by 119.73% to $74.5 million in 2023, then soared by 66.47% to $124.0 million in 2024, then tumbled by 98.39% to $2.0 million in 2025, then surged by 6000.0% to $122.0 million in 2026.
• Business Quant data shows RARE's Receivables at $122.0 million in Q1 2026, $2.0 million in Q4 2025, and $114.6 million in Q3 2025.